Background {#Sec1}
==========

About half of the patients presenting with ST-elevation myocardial infarction (STEMI) have multivessel disease. Compared with STEMI patients with single-vessel disease, STEMI patients with multivessel disease have a worse prognosis \[[@CR1]--[@CR3]\].

The current guidelines recommend intervention in the infarct-related artery only during primary percutaneous coronary intervention (PCI) except in haemodynamically unstable patients \[[@CR4]\]; this is mainly due to the fact that evidence supporting immediate (preventive) intervention in the non-infarct-related artery is a matter of debate.

There are controversial data regarding infarct-related artery only revascularisation (IRA-PCI) versus multivessel revascularisation (MV-PCI) in STEMI patients with multivessel disease \[[@CR5]--[@CR19]\].

Previously, other meta-analyses assessed MV-PCI versus IRA-PCI; however, in those meta-analysis, MV-PCI was defined as same stage PCI as well as staged PCI days after the primary PCI. Furthermore, the results of the most recent trials were not included \[[@CR20]--[@CR23]\].

We performed a meta-analysis comparing outcome in MV-PCI versus IRA-PCI during the index of primary PCI in STEMI patients with multivessel disease.

Methods {#Sec2}
=======

Literature review {#Sec3}
-----------------

The literature search was performed from Cochrane Library, EMBASE and MEDLINE, from January 2014 to December 2014. The terms "ST-elevation myocardial infarction", "coronary angioplasty", "percutaneous coronary intervention", "multi-vessel", "non-culprit", "culprit coronary revascularisation", "complete revascularisation", "myocardial infarction" and their variations were used as keywords. The search was limited to records in humans and English language articles.

Study selection {#Sec4}
---------------

Two reviewers independently screened all citations for eligibility. Both randomised controlled trials (RCTs) and cohort studies comparing multivessel versus culprit-only PCI in patients with STEMI and multivessel coronary artery disease treated with primary PCI were included. Studies enrolling patients with other than STEMI or comparing alternative revascularisation strategies were excluded. Full-text citations and abstracts were selected and independently screened for eligibility in the meta-analysis. The unpublished Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT) was also included because of its importance for this meta-analysis \[[@CR20]\]. Quality of abstracted studies was assessed using the Cochrane Collaboration's tool for assessing risk of bias \[[@CR24]\].

Information on study design, inclusion and exclusion criteria, number of patients and clinical outcome was extracted by two investigators. Disagreements were resolved by consensus. Finally, all co-authors had full access to all study data and take responsibility for the integrity of the data and the accuracy of the data analysis.

Definitions {#Sec5}
-----------

MV-PCI was defined as PCI of the infarct-related artery (IRA) and non-IRA performed during the index primary PCI procedure for STEMI. IRA-PCI is defined as the PCI of the IRA only during the index primary PCI procedure. Major adverse cardiac event (MACE) was defined as the composite of death, re-infarction and revascularisation. Bleeding included both minor and major bleeding.

Endpoints/data abstraction {#Sec6}
--------------------------

The primary clinical endpoint was all-cause mortality. Secondary endpoints were re-infarction, revascularisation, bleeding and MACE.

Statistical analysis {#Sec7}
--------------------

Continuous data were expressed as mean ± standard deviation and dichotomous data as absolute values and percentages. Mantel--Haenszel model was used to construct random effects summary odds ratios (ORs) and risk differences. All analyses were performed using Review Manager (RevMan, Version 5.0, The Nordic Cochrane Centre, The Cochrane Collaboration 2008) and SAS 9.3, (SAS Institute, Cary, NC). *p*-Value \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

The search yielded 15 studies \[[@CR5]--[@CR19]\]: 5 RCTs and 10 cohort studies. The characteristics of the included studies are shown in Table [1](#Tab1){ref-type="table"}. A total of 35,975 patients comprised the study population including 1134 (3.2 %) patients from RCTs. MV-PCI was performed in 5109 (12.2 %) patients, and 30,939 (85.8 %) patients underwent IRA-PCI.Table 1Study characteristicsStudyDesignSubjectsInclusion criteriaExclusion criteriaPrimary endpointMean length follow-upCavenderCohort study28,936STEMI with CAD of \> 1 major arteryLM, staged PCI (multiple PCIs before hospital discharge), thrombolyticIn-hospital mortalityIn-hospitalCorpusCohort study532STEMI with \> 70 % stenosis of ≥ 2 arteriesPCI of graft or after angioplasty, LM, planned staged revascularisationMACE12 monthsDi MarioRandomised69STEMI with MVD and 1--3 lesions in non-culprit artery technically amenable to revascularisation by stentLesion in vein and arterial grafts, prior angioplasty, thrombolytic, cardiogenic shock, LMRepeat revascularisation12 monthsDziewierzCohort study777STEMI with MVD 2--3 lesions in non-culprit arteryCABGAll-cause mortality12 monthsHannanCohort study1006STEMI with MVDLM disease, prior thrombolysis, prior CABG, cardiogenic shock, missing EFAll-cause mortality42 monthsKhattabCohort study73STEMI with \> 70 % stenosis of ≥ 2 coronary arteries or major branchesNon-IRA diameter \< 2.5 mm, LM disease, previous MIMACE12 monthsKornowskiCohort study668STEMI with MVDTIMI flow \< 3 in non-IRAMACE12 monthsOchalaRandomised92STEMI with \> 70 % stenosis of ≥ 2 coronary arteries, successful PCI of IRACardiogenic shock, LM disease, pervious CABG, renal insufficiency, severe valvular diseaseImprovement in LVEF6 monthsPolitiRandomised214STEMI with \> 70 % stenosis of ≥ 2 coronary arteries or major branchesCardiogenic shock, LM \> 50 %, pervious CABG, severe valvular heart disease or unsuccessful procedureMACE30 monthsQarawaniCohort study120STEMI with \> 70 % multivessel narrowingCardiogenic shock, LM diseaseClinical outcome12 monthsRoeCohort study129STEMI with ≥ 50 % stenosis of ≥ 1 non-culprit artery in addition to culprit IRAPCI of branch vessels of IRA, LM diseaseMACE (death, re-MI, and revascularisation)6 monthsTomaCohort study2201STEMI with \> 70 % stenosis of \> 1 major epicardial artery and/or a non-IRA requiring interventionPCI on LM, second intervention in the culprit arteryMACE (death, CHF, shock)3 monthsVaraniCohort study399STEMI with \> 70 % stenosis of ≥ 2 epicardial arteries or major branchesOcclusion after prior angioplasty, cardiogenic shock, pulmonary oedemaDeath and repeat revascularisation1 monthWaldRandomised465STEMI with ≥ 50 % stenosis of ≥ 1 non-IRA in addition to IRACardiogenic shock, LM \> 50 %, pervious CABGMACE23 monthsGershlickRandomised294STEMI with \> 70 % stenosis of ≥ 2 epicardial arteries or major branches (\> 2 mm)Cardiogenic shock, previous MI, pervious CABG, chronic kidney disease, CTOMACE12 months*CABG* coronary artery bypass graft, *CAD* coronary artery disease, *CHF* congestive heart failure, *CTO* chronic total occlusion, *IRA* infarct-related artery, *LM* left main artery, *LVEF* left ventricular ejection fraction, *MACE* major adverse cardiac events, *MI* myocardial infarction, *MVD* multivessel disease, *PCI* percutaneous coronary intervention, *STEMI* ST-elevation myocardial infarction, *TIMI* thrombolysis in myocardial infarction

Patient characteristics {#Sec9}
-----------------------

Table [2](#Tab2){ref-type="table"} shows the baseline characteristics of the study population. The vast majority of the studies excluded patients with cardiogenic shock and in two trials cardiogenic shock was not reported.Table 2Baseline characteristicsAgeMale (%)Diabetes (%)Anterior MI (%)Cardiogenic shock (%)StudyMV-PCIIRA-PCIMV-PCIIRA-PCIMV-PCIIRA-PCIMV-PCIIRA-PCIMV-PCIIRA-PCICavender606271.572.124.723.4NRNR13.810.3Corpus646370701917NRNR3.33.4Di Mario646588.284.611.541.551.958.8ExcludedExcludedDziewier686872.272.2NRNRNRNRNot reportedNot reportedHannanNRNR77.575.523.721.4NRNRExcludedExcludedKhattab6965757871657543.64.4Kornowski6263.580.979.615.318.140.635.1Not reportedNot reportedOchala656772.975313445.845.4ExcludedExcludedPoliti656576.977.814214843ExcludedExcludedQarawani6667626113165152ExcludedExcludedRoe646377.265.8372946412828Toma646474731220564833Varani696768.767NRNR4934ExcludedExcludedWald6262768135482939ExcludedExcludedGershlick6565857712.914.33635.6ExcludedExcluded*IRA-PCI* infarct-related artery only revascularisation, *MI* myocardial infarction, *MV-PCI* multivessel revascularisation, *NR* not reported

Clinical outcomes {#Sec10}
-----------------

The primary endpoint, all-cause mortality, was significantly higher in the MV-PCI (8.5 %) compared with the IRA-PCI (5.4 %) group (OR 1.57, 95 % CI 1.40--1.76, *p* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}). However, analysis limited to the five RCTs only showed no significant difference in mortality rate between MV-PCI and IRA-PCI (OR 0.74, 95 % CI 0.43--1.26, *p* = 0.27).Fig. 1Forest plot of all-cause mortality

Secondary endpoints {#Sec11}
-------------------

Rates of re-infarction (OR 0.54, 95 % CI 0.34--0.88, *p* = 0.01) and revascularisation (OR 0.67, 95 % CI 0.48--0.93, *p* = 0.002) were lower in the MV-PCI group. This was found for both randomised and cohort trials (Fig. [2a](#Fig2){ref-type="fig"} and [b](#Fig2){ref-type="fig"}).Fig. 2**a** Forest plot of re-infarction. **b** Forest plot of re-percutaneous coronary intervention

Bleeding complications (major and minor) occurred more often in the MV-PCI group: 6.2 versus 5.1 %, (OR 1.24, 95 % CI 1.08--1.42, *p* = 0.002) and this was mainly found in the cohort studies (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot of bleeding (major and minor)

MACE was comparable between the two groups: 19 versus 19.5 % (OR 0.94, 95 % CI 0.74--1.19, *p* = 0.59). In the RCT trials, MACE was significantly lower in patients undergoing MV-PCI compared with the IRA-PCI group (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Forest plot of major adverse cardiac events (death, re-infarction and re-percutaneous coronary intervention)

Discussion {#Sec12}
==========

In this large scale meta-analysis, we found that PCI of the IRA and non-IRA performed during the index primary PCI procedure for STEMI, compared with IRA-only PCI, is associated with a higher mortality rate and more bleeding complications, but less re-infarction and revascularisation. Rates of MACE were comparable between the two groups. However, there was a clear difference in outcome between the randomised trials and cohort studies. In the cohort studies, mortality and bleeding complications were significantly higher in the MV-PCI group; however, these were not significantly different in the randomised trials between the MV-PCI group versus IRA-PCI group (Figs. [1](#Fig1){ref-type="fig"} and [4](#Fig4){ref-type="fig"}).

Approximately 40--65 % of patients with STEMI have multivessel disease with increased risk of morbidity and mortality compared with single-vessel disease \[[@CR1]--[@CR3]\]. The underlying mechanism for this adverse prognosis may be plaque instability, impaired myocardial perfusion and contractility, arrhythmia and death.

The potential advantages of MV-PCI during the index primary PCI may prevent recurrent ischaemia and infarction by decreasing total ischaemia and improvement in myocardial function \[[@CR25], [@CR26]\]. Plaque instability may not be limited to the IRA but may involve other territories in the coronary vasculature. Moreover, complete revascularisation has been associated with improved long-term clinical outcome in patients with stable coronary artery disease. Finally, patients and clinicians may be more comfortable with complete revascularisation rather than medical therapy for angiographically significant residual coronary stenosis, especially if they are associated with a large territory of myocardial jeopardy \[[@CR27]--[@CR30]\].

However, multivessel PCI also has disadvantages. In the acute phase of STEMI, intervention of a non-culprit lesion may result in unnecessary haemodynamic compromise during PCI with balloon inflations or vessel-related complications (dissection, no-reflow) at a time when the patient has regional myocardial compromise. Given the extended duration of the intervention, increased contrast load and additional adverse peri-procedural outcomes may occur. Another important concern is poor assessment of lesion severity in non-culprit artery \[[@CR22]\]. Hanratty et al. \[[@CR30]\] demonstrated that 21 % of the non-culprit lesions are overestimated at time of AMI, and this may affect unnecessary revascularisation and inappropriate decision making. The severity of the non-culprit artery was judged visually and PCI of the non-IRA was not ischaemia guided in any of the studies included in this meta-analysis.

There is only one randomised study in which revascularisations on the non-IRA was guided by fractional flow reserve (FFR). FFR of the non-IRA was performed 7.5 days after primary PCI, and they found functional stenosis severity of non-culprit lesions is frequently overestimated and invasive strategy for non-culprit lesions did not lead to an increase in ejection fraction or a reduction in MACE \[[@CR31]\].

Prior meta-analyses in this area have reported varying results due to differences in study design, comparison of different groups and different analytical methods \[[@CR20]--[@CR23]\]. Vlaar et al. \[[@CR20]\] found that the strategy of staged PCI resulted in lower short- and long-term mortality compared with MV-PCI or IRA-PCI. Bangalore et al. \[[@CR21]\] found that MV-PCI compared with IRA-PCI resulted in similar long-term mortality but a lower long-term rate of MACE. A recent meta-analysis showed that MV-PCI compared with IRA-PCI resulted in worse outcomes in cohort studies, but not in the randomised clinical trials \[[@CR22]\]. This is in line with our findings.

Furthermore, Bainey et al. \[[@CR23]\] found that staged multivessel PCI was superior to multivessel PCI during the index procedure.

The difference in outcome between the IRA-only and MV-PCI group may not only be due to revascularisation, differences in baseline may also play an important role. Patients in the MV-PCI group have a higher baseline risk evidenced by a higher proportion of anterior myocardial infarction and more cardiogenic shock.

Based on the current evidence, we think that in the acute phase of STEMI, revascularisation should be limited to the IRA only, except in patients with haemodynamic instability, as recommended by the current guidelines \[[@CR4]\]. Staged and ischaemia-driven revascularisation of non-culprit lesions may be the treatment strategy for STEMI patients with multivessel disease. Further studies are needed to confirm this. The current ongoing COMPLETE and COMPARE ACUTE trials are studying these issues.

Limitations {#Sec13}
===========

This meta-analysis was not performed on individual patient data. Caution should be exercised in the interpretation of the results, given the potential clinical heterogeneity among trials, due to varying patient populations and potential treatment bias. No information was available with regard to extent of coronary disease, use of drug-eluting stents, duration of dual antiplatelet therapy and access site. The short follow-up period of some studies is another important limitation. Furthermore, only a minority of the patients (14.2 %) undergo MV-PCI during the index procedure, so it is hard to draw definitive conclusions based on this meta-analysis.

In addition, no information was available regarding referral method, ambulance versus referring via non-PCI centres, factors that may affect total ischaemic time \[[@CR32]\].

Finally, although the STEMI and non-STEMI are not uniquely related to different pathophysiological mechanisms \[[@CR33]\], our results cannot be applied to non-STEMI patients with multivessel disease.

Conclusion {#Sec14}
==========

Multivessel PCI during the index of primary PCI in STEMI patients is associated with a higher mortality and more bleeding, but a lower risk of re-intervention and re-infarction. Additional large-scale randomised trials are needed to guide the therapy and the timing for these patient subsets.
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